Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-05

AUTHORS

Shelley R. Salpeter

ABSTRACT

Backgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease. More... »

PAGES

405-414

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005

DOI

http://dx.doi.org/10.2165/00002512-200421060-00005

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044511580

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15084142


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic alpha-2 Receptor Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pulmonary Disease, Chronic Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.415182.b", 
          "name": [
            "Stanford University School of Medicine, Stanford, California, USA", 
            "Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salpeter", 
        "givenName": "Shelley R.", 
        "id": "sg:person.012160071167.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-199142030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021698570", 
          "https://doi.org/10.2165/00003495-199142030-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199207010-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053525213", 
          "https://doi.org/10.2165/00002018-199207010-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050435", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050389605", 
          "https://doi.org/10.1007/s002280050435"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-197600111-00025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045796379", 
          "https://doi.org/10.2165/00003495-197600111-00025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00614551", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009739834", 
          "https://doi.org/10.1007/bf00614551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042256952", 
          "https://doi.org/10.1007/s002280050399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03259844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037870887", 
          "https://doi.org/10.1007/bf03259844"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05", 
    "datePublishedReg": "2004-05-01", 
    "description": "Background\u03b22-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that \u03b22-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of \u03b22-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that \u03b22-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that \u03b22-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of \u03b22-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of \u03b22-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of \u03b2-adrenergic stimulation that \u03b22-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, \u03b22-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether \u03b22-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00002512-200421060-00005", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100990", 
        "issn": [
          "1170-229X", 
          "1179-1969"
        ], 
        "name": "Drugs & Aging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "chronic obstructive pulmonary disease", 
      "adverse cardiovascular events", 
      "obstructive airways disease", 
      "\u03b22-adrenoceptor agonists", 
      "agonist use", 
      "congestive heart failure", 
      "sudden cardiac death", 
      "case-control study", 
      "cardiovascular events", 
      "airway disease", 
      "cardiovascular safety", 
      "heart failure", 
      "cardiac death", 
      "heart rate", 
      "concomitant cardiac conditions", 
      "placebo-controlled trial", 
      "concomitant cardiovascular disease", 
      "management of asthma", 
      "obstructive pulmonary disease", 
      "MethodsA systematic review", 
      "potassium concentration", 
      "pulmonary disease", 
      "agonist treatment", 
      "respiratory tolerance", 
      "cardiac arrest", 
      "asthma attacks", 
      "myocardial infarction", 
      "single doses", 
      "cardiovascular disease", 
      "cardiac conditions", 
      "adrenergic stimulation", 
      "systematic review", 
      "agonists", 
      "disease", 
      "placebo", 
      "asthma", 
      "patients", 
      "risk", 
      "trials", 
      "degree of risk", 
      "death", 
      "treatment", 
      "safety", 
      "bronchodilators", 
      "morbidity", 
      "ischaemia", 
      "infarction", 
      "failure", 
      "arrhythmias", 
      "mortality", 
      "doses", 
      "study", 
      "evidence", 
      "stimulation", 
      "arrest", 
      "events", 
      "causal one", 
      "association", 
      "use", 
      "rate", 
      "new users", 
      "review", 
      "concentration", 
      "management", 
      "effect", 
      "tolerance", 
      "data", 
      "addition", 
      "degree", 
      "attacks", 
      "conditions", 
      "one", 
      "users"
    ], 
    "name": "Cardiovascular Safety of \u03b22-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease", 
    "pagination": "405-414", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044511580"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00002512-200421060-00005"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15084142"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00002512-200421060-00005", 
      "https://app.dimensions.ai/details/publication/pub.1044511580"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_390.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00002512-200421060-00005"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      21 PREDICATES      115 URIs      100 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00002512-200421060-00005 schema:about N2f015628f4a44a428dce029c4ccccda9
2 N3915ed9bb84b4644a3617365065b98f7
3 N401dd3aafb4e4a1e82b1ac3192972f95
4 N5d1007d3a2204c11946544cdd8e48858
5 N5dd318da02c948cd9cd3fb16fa6ee1d6
6 N98e13b587ad644e8ac217409c1284550
7 Nbd64adb3685d48209e44b9df3b9be729
8 Nc7b30d23bb12413ebfbc339e9f95b7aa
9 Ncc60b535cef546ba9ee55e3e73b5dd93
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author Nf14e2cfd53ab4d2fb3f80f571fe6a466
13 schema:citation sg:pub.10.1007/bf00614551
14 sg:pub.10.1007/bf03259844
15 sg:pub.10.1007/s002280050399
16 sg:pub.10.1007/s002280050435
17 sg:pub.10.2165/00002018-199207010-00007
18 sg:pub.10.2165/00003495-197600111-00025
19 sg:pub.10.2165/00003495-199142030-00007
20 schema:datePublished 2004-05
21 schema:datePublishedReg 2004-05-01
22 schema:description Backgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.
23 schema:genre article
24 schema:isAccessibleForFree false
25 schema:isPartOf N1ac832ff52c948f28b968b46884fddc9
26 N3eab9cea3fc842829600c56230888632
27 sg:journal.1100990
28 schema:keywords MethodsA systematic review
29 addition
30 adrenergic stimulation
31 adverse cardiovascular events
32 agonist treatment
33 agonist use
34 agonists
35 airway disease
36 arrest
37 arrhythmias
38 association
39 asthma
40 asthma attacks
41 attacks
42 bronchodilators
43 cardiac arrest
44 cardiac conditions
45 cardiac death
46 cardiovascular disease
47 cardiovascular events
48 cardiovascular safety
49 case-control study
50 causal one
51 chronic obstructive pulmonary disease
52 concentration
53 concomitant cardiac conditions
54 concomitant cardiovascular disease
55 conditions
56 congestive heart failure
57 data
58 death
59 degree
60 degree of risk
61 disease
62 doses
63 effect
64 events
65 evidence
66 failure
67 heart failure
68 heart rate
69 infarction
70 ischaemia
71 management
72 management of asthma
73 morbidity
74 mortality
75 myocardial infarction
76 new users
77 obstructive airways disease
78 obstructive pulmonary disease
79 one
80 patients
81 placebo
82 placebo-controlled trial
83 potassium concentration
84 pulmonary disease
85 rate
86 respiratory tolerance
87 review
88 risk
89 safety
90 single doses
91 stimulation
92 study
93 sudden cardiac death
94 systematic review
95 tolerance
96 treatment
97 trials
98 use
99 users
100 β2-adrenoceptor agonists
101 schema:name Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease
102 schema:pagination 405-414
103 schema:productId N6fcc3891bbb94976904fba003cf0f70f
104 N8c9d8cb869084385a11f1e13fbcfeda2
105 N963d3333e2c24f59966c2528b0f7529b
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044511580
107 https://doi.org/10.2165/00002512-200421060-00005
108 schema:sdDatePublished 2022-08-04T16:55
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N849af56899f04f478f7b524a49600628
111 schema:url https://doi.org/10.2165/00002512-200421060-00005
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N1ac832ff52c948f28b968b46884fddc9 schema:volumeNumber 21
116 rdf:type schema:PublicationVolume
117 N2f015628f4a44a428dce029c4ccccda9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Pulmonary Disease, Chronic Obstructive
119 rdf:type schema:DefinedTerm
120 N3915ed9bb84b4644a3617365065b98f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Adrenergic alpha-2 Receptor Agonists
122 rdf:type schema:DefinedTerm
123 N3eab9cea3fc842829600c56230888632 schema:issueNumber 6
124 rdf:type schema:PublicationIssue
125 N401dd3aafb4e4a1e82b1ac3192972f95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Asthma
127 rdf:type schema:DefinedTerm
128 N5d1007d3a2204c11946544cdd8e48858 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Animals
130 rdf:type schema:DefinedTerm
131 N5dd318da02c948cd9cd3fb16fa6ee1d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cardiovascular Diseases
133 rdf:type schema:DefinedTerm
134 N6fcc3891bbb94976904fba003cf0f70f schema:name dimensions_id
135 schema:value pub.1044511580
136 rdf:type schema:PropertyValue
137 N849af56899f04f478f7b524a49600628 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N8c9d8cb869084385a11f1e13fbcfeda2 schema:name pubmed_id
140 schema:value 15084142
141 rdf:type schema:PropertyValue
142 N963d3333e2c24f59966c2528b0f7529b schema:name doi
143 schema:value 10.2165/00002512-200421060-00005
144 rdf:type schema:PropertyValue
145 N98e13b587ad644e8ac217409c1284550 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adrenergic beta-Agonists
147 rdf:type schema:DefinedTerm
148 Nbd64adb3685d48209e44b9df3b9be729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Randomized Controlled Trials as Topic
150 rdf:type schema:DefinedTerm
151 Nc7b30d23bb12413ebfbc339e9f95b7aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 Ncc60b535cef546ba9ee55e3e73b5dd93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Case-Control Studies
156 rdf:type schema:DefinedTerm
157 Nf14e2cfd53ab4d2fb3f80f571fe6a466 rdf:first sg:person.012160071167.38
158 rdf:rest rdf:nil
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
163 schema:name Cardiorespiratory Medicine and Haematology
164 rdf:type schema:DefinedTerm
165 sg:journal.1100990 schema:issn 1170-229X
166 1179-1969
167 schema:name Drugs & Aging
168 schema:publisher Springer Nature
169 rdf:type schema:Periodical
170 sg:person.012160071167.38 schema:affiliation grid-institutes:grid.415182.b
171 schema:familyName Salpeter
172 schema:givenName Shelley R.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38
174 rdf:type schema:Person
175 sg:pub.10.1007/bf00614551 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009739834
176 https://doi.org/10.1007/bf00614551
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/bf03259844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037870887
179 https://doi.org/10.1007/bf03259844
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/s002280050399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042256952
182 https://doi.org/10.1007/s002280050399
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/s002280050435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050389605
185 https://doi.org/10.1007/s002280050435
186 rdf:type schema:CreativeWork
187 sg:pub.10.2165/00002018-199207010-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053525213
188 https://doi.org/10.2165/00002018-199207010-00007
189 rdf:type schema:CreativeWork
190 sg:pub.10.2165/00003495-197600111-00025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045796379
191 https://doi.org/10.2165/00003495-197600111-00025
192 rdf:type schema:CreativeWork
193 sg:pub.10.2165/00003495-199142030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021698570
194 https://doi.org/10.2165/00003495-199142030-00007
195 rdf:type schema:CreativeWork
196 grid-institutes:grid.415182.b schema:alternateName Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA
197 schema:name Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA
198 Stanford University School of Medicine, Stanford, California, USA
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...